Success rate of microsatellite instability examination and complete response with pembrolizumab in biliary tract cancer

Success rate of microsatellite instability examination and complete response with pembrolizumab in biliary tract cancer

Abstract Background and Aim The success rate of microsatellite instability (MSI) examination in biliary tract cancer (BTC) and the treatment outcomes of pembrolizumab in patients with MSI‐high (MSI‐H) BTC have not been fully investigated. We examined the success rate of MSI examination and the rate...

Full description

Bibliographic Details
Main Authors:	Yugo Kai, Kenji Ikezawa, Ryoji Takada, Kazuma Daiku, Shingo Maeda, Yutaro Abe, Takuo Yamai, Nobuyasu Fukutake, Tasuku Nakabori, Hiroyuki Uehara, Shigenori Nagata, Hiroshi Wada, Kazuyoshi Ohkawa
Format:	Article
Language:	English
Published:	Wiley 2021-06-01
Series:	JGH Open
Subjects:	biliary tract neoplasms cholangiocarcinoma endoscopic ultrasound‐guided fine‐needle aspiration microsatellite instability pembrolizumab
Online Access:	https://doi.org/10.1002/jgh3.12576

Similar Items

A case of refractory tumor bleeding from an ampullary adenocarcinoma: Compression hemostasis with a self‐expandable metallic stent
by: Kazuma Daiku, et al.
Published: (2022-04-01)

Primary Pancreatic Mantle Cell Lymphoma Diagnosed via Endoscopic Ultrasound-Guided Fine-Needle Aspiration
by: Takuo Yamai, et al.
Published: (2021-06-01)

Successful pembrolizumab treatment of microsatellite instability‐high intrahepatic cholangiocarcinoma: A case report
by: Yuki Ikeda, et al.
Published: (2021-04-01)

The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer
by: Ryoji Takada, et al.
Published: (2021-09-01)

Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S‐1 as second‐line chemotherapy in metastatic pancreatic cancer
by: Kenji Ikezawa, et al.
Published: (2021-06-01)

Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel.
by: Takuo Yamai, et al.
Published: (2022-01-01)

Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel
by: Takuo Yamai, et al.
Published: (2022-01-01)

5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice
by: Takuo Yamai, et al.
Published: (2022-04-01)

Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection
by: Tasuku Nakabori, et al.
Published: (2022-05-01)

Gallbladder neuroendocrine carcinoma: An important differential diagnosis of gallbladder adenocarcinoma
by: Kenji Ikezawa, et al.
Published: (2021-06-01)

Significant response to pembrolizumab plus lenvatinib in Epstein–Barr-virus-associated intrahepatic cholangiocarcinoma: a case report
by: Lisha Li, et al.
Published: (2024-12-01)

Durable response to the combination of pembrolizumab and nab-paclitaxel in a metastatic extrahepatic cholangiocarcinoma: A case report and literature review
by: Sirui Tan, et al.
Published: (2022-11-01)

An age-group analysis on the efficacy of chemotherapy in older adult patients with metastatic biliary tract cancer: a Japanese cancer registry cohort study
by: Takeru Hirao, et al.
Published: (2023-08-01)

Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high
by: Motohiro Fujiwara, et al.
Published: (2020-03-01)

New Screening System Using Forward-Viewing Radial Endoscopic Ultrasound and Magnetic Resonance Imaging for High-Risk Individuals With Familial History of Pancreatic Cancer
by: Reiko Ashida, et al.
Published: (2022-06-01)

Portal Vein Aneurysm in a Patient with Cirrhosis Type C Controlled by Direct-Acting Antiviral Treatment
by: Sena Higashi, et al.
Published: (2024-02-01)

Establishment of organoids using residual samples from saline flushes during endoscopic ultrasound-guided fine-needle aspiration in patients with pancreatic cancer
by: Kenji Ikezawa, et al.
Published: (2022-01-01)

Predictive Factors for Pancreatic Cancer and Its Early Detection Using Special Pancreatic Ultrasonography in High-Risk Individuals
by: Junko Fukuda, et al.
Published: (2021-01-01)

Durable response to pembrolizumab in microsatellite instability‐high advanced adrenocortical carcinoma
by: Masaya Senda, et al.
Published: (2023-11-01)

A case of multiple myeloma with pancreatic involvement diagnosed via endoscopic ultrasound‐guided fine needle aspiration
by: Erika Hiraga, et al.
Published: (2023-04-01)

Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
by: Evidio Domingo-Musibay, et al.
Published: (2018-06-01)

Bronchiolitis Obliterans after Combination Immunotherapy with Pembrolizumab and Ipilimumab
by: Amulya Balagani, et al.
Published: (2018-07-01)

Pembrolizumab-Associated Hypoparathyroidism: A Single Case Report
by: Israa Mahmood, PharmD, et al.
Published: (2021-01-01)

Pembrolizumab for the treatment of Progressive Multifocal Leukoencephalopathy (PML) in a patient with AIDS: A case report and literature review
by: Tulika Chatterjee, et al.
Published: (2022-01-01)

A case of relapsing aseptic meningitis under excellent tumor response to pembrolizumab in microsatellite instability-high recurrent endometrial cancer
by: Daito Noguchi, et al.
Published: (2021-11-01)

Maxillary osteonecrosis linked to Pembrolizumab therapy: a case report
by: Gosselin-Rousselle Louise, et al.
Published: (2024-01-01)

Pembrolizumab-Related Side Effects: Acute Renal Failure and Severe Neurological Toxicity
by: Gabriele Fasano, et al.
Published: (2022-01-01)

Efficacy of Pembrolizumab in Advanced Melanoma: A Narrative Review
by: Giulio Rizzetto, et al.
Published: (2023-08-01)

Pembrolizumab-Induced Nasal Polyposis: The First Reported Case
by: Justin M. Hintze, et al.
Published: (2023-07-01)

Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab
by: Hideo Oishi, MD, et al.
Published: (2020-10-01)

Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
by: Hao‐Chun Chang, et al.
Published: (2020-08-01)

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial
by: Masatoshi Kudo, et al.
Published: (2021-04-01)

A Fatal Case of Pembrolizumab-Induced Myocarditis in Non–Small Cell Lung Cancer
by: Max Cohen, BS, et al.
Published: (2020-03-01)

Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma
by: Jonathan T. Hunt, et al.
Published: (2021-08-01)

Diabetes Mellitus and diabetic ketoacidosis associated with pembrolizumab
by: Karla Lauš, et al.
Published: (2023-01-01)

Development of drug-induced arthritis in a glioblastoma patient treated with pembrolizumab
by: Casey B Brown, et al.
Published: (2018-01-01)

A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab
by: Masahiro Sako, et al.
Published: (2022-01-01)

Dermatitis bullosa como efecto secundario a pembrolizumab
by: Alícia da Silva Oliveira, et al.
Published: (2022-01-01)

Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment
by: Charlée Nardin, et al.
Published: (2019-07-01)

Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer
by: Ryoji Takada, et al.
Published: (2023-07-01)